within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD58_CefiximeAndBetaLactamaseInhibitor;

model CefiximeAndBetaLactamaseInhibitor
  extends Pharmacolibrary.Drugs.ATC.J.J01DD58;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01DD58</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cefixime is a third-generation oral cephalosporin antibiotic used to treat a range of bacterial infections, including respiratory tract, urinary tract, and sexually transmitted infections. Beta-lactamase inhibitors are agents that extend the spectrum of beta-lactam antibiotics by inhibiting beta-lactamase enzymes produced by bacteria, which would otherwise degrade the antibiotic. The fixed-dose combination of cefixime and a beta-lactamase inhibitor is intended to overcome resistance in beta-lactamase-producing organisms. As of now, such fixed-dose combinations are used in some countries but are not broadly approved in the US/Europe.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for the combination product (cefixime and beta-lactamase inhibitor) in healthy adults, based on known PK of cefixime and class properties of oral beta-lactamase inhibitors.</p><h4>References</h4><ol><li><p>Stewart, AG, et al., &amp; Paterson, DL (2023). In-vitro activity of oral third-generation cephalosporins plus clavulanate against ESBL-producing Enterobacterales isolates from the MERINO trial. <i>International journal of antimicrobial agents</i> 62(2) 106858–None. DOI:<a href=\"https://doi.org/10.1016/j.ijantimicag.2023.106858\">10.1016/j.ijantimicag.2023.106858</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37211261/\">https://pubmed.ncbi.nlm.nih.gov/37211261</a></p></li><li><p>Birgy, A, et al., &amp; Bonacorsi, S (2021). Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections. <i>The Journal of antimicrobial chemotherapy</i> 76(11) 2839–2846. DOI:<a href=\"https://doi.org/10.1093/jac/dkab289\">10.1093/jac/dkab289</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34453533/\">https://pubmed.ncbi.nlm.nih.gov/34453533</a></p></li><li><p>Casellas, JM, et al., &amp; Farinati, AE (1993). Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. <i>Pathologie-biologie</i> 41(4) 385–391. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8233640/\">https://pubmed.ncbi.nlm.nih.gov/8233640</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end CefiximeAndBetaLactamaseInhibitor;
